LON:CEL Celadon Pharmaceuticals (CEL) Share Price, News & Analysis → Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes) (Ad) Free CEL Stock Alerts GBX 100.50 0.00 (0.00%) (As of 03:22 AM ET) Add Compare Share Share Today's Range 95▼ 10550-Day Range 78.50▼ 12052-Week Range 73.44▼ 180Volume360 shsAverage Volume37,184 shsMarket Capitalization£66.07 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 222.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlines Get Celadon Pharmaceuticals alerts: Email Address Celadon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside121.4% UpsideGBX 222.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCeladon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCeladon Pharmaceuticals has received no research coverage in the past 90 days.Read more about Celadon Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CEL. Previous Next 0.0 Dividend Strength Dividend YieldCeladon Pharmaceuticals does not currently pay a dividend.Dividend GrowthCeladon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CEL. Previous Next 2.3 News and Social Media Coverage News SentimentCeladon Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Celadon Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for CEL on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celadon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders65.50% of the stock of Celadon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.36% of the stock of Celadon Pharmaceuticals is held by institutions.Read more about Celadon Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Celadon Pharmaceuticals is -717.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celadon Pharmaceuticals is -717.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCeladon Pharmaceuticals has a P/B Ratio of 20.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Celadon Pharmaceuticals Stock (LON:CEL)Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.Read More CEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CEL Stock News HeadlinesMay 23, 2024 | lse.co.ukTRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pactMay 22, 2024 | americanbankingnews.comCeladon Pharmaceuticals (LON:CEL) Trading 4.9% Higher February 28, 2024 | morningstar.comCeladon Pharmaceuticals PLC CELDecember 14, 2023 | lse.co.ukCeladon announces start of cannabis supply for two UK companiesDecember 12, 2023 | lse.co.ukTRADING UPDATES: Celadon Pharma raises GBP2.0 million via placingDecember 4, 2023 | msn.comUK's First Medical Marijuana Clinical Trial Gets Underway: National Health Service Remains CautiousNovember 16, 2023 | lse.co.ukCeladon shares rise on supply contract worth up to GBP26 millionOctober 13, 2023 | marketwatch.comCeladon Pharmaceuticals to Raise GBP1 Mln via Discounted Placing, SubscriptionOctober 1, 2023 | finance.yahoo.comCeladon Pharmaceuticals First Half 2023 Earnings: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)September 28, 2023 | lse.co.ukCeladon Pharmaceuticals interim loss narrows; optimistic for futureSeptember 5, 2023 | lse.co.ukCeladon shares rise on second UK contract win for cannabis productSeptember 5, 2023 | marketwatch.comCeladon Pharmaceuticals Enters New Contract Worth Up to GBP1.2 Mln in RevenueAugust 22, 2023 | finance.yahoo.comOwning 61% in Celadon Pharmaceuticals Plc (LON:CEL) means that insiders are heavily invested in the company's futureAugust 1, 2023 | ca.finance.yahoo.comCEL.L - Celadon Pharmaceuticals PlcAugust 1, 2023 | lse.co.ukCeladon receives approval for 5,000 patient clinical cannabis trialJune 9, 2023 | finance.yahoo.comInvestors’ Chronicle: Oxford Metrics, N Brown, Celadon PharmaceuticalsJune 5, 2023 | lse.co.ukCeladon Pharmaceuticals loss widens; confident amid three-year dealMay 30, 2023 | lse.co.ukCeladon secures GBP7 million credit facility as product demand growsMay 30, 2023 | marketwatch.comCeladon Pharmaceuticals Shares Rise on New GBP7 Mln Line of CreditMay 24, 2023 | lse.co.ukCeladon signs commercial cannabis supply agreement with UK firmMay 24, 2023 | lse.co.ukCORRECT: Celadon signs commercial cannabis supply agreement in UKApril 20, 2023 | finance.yahoo.comC15 Solutions Anticipates Substantial Growth in European Cannabis Market Through Innovative Tech PlatformMarch 15, 2023 | finance.yahoo.comJames Short Celadon Pharmaceuticals Plc's (LON:CEL) CEO is the most bullish insider, and their stock value gained 162%last weekMarch 14, 2023 | thetimes.co.ukFresh permit for cannabis lifts CeladonMarch 14, 2023 | marketwatch.comCeladon Pharmaceuticals Shares Jump as Sale of Pharmaceutical Cannabis Product GrantedSee More Headlines Receive CEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:CEL CUSIPN/A CIKN/A Webwww.celadonpharma.co.uk Phone44 20 3150 0252FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 222.50 High Stock Price TargetGBX 235 Low Stock Price TargetGBX 210 Potential Upside/Downside+121.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-7,140,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-142.14% Return on Assets-34.58% Debt Debt-to-Equity Ratio148.29 Current Ratio2.62 Quick Ratio6.97 Sales & Book Value Annual Sales£11,258.00 Price / Sales5,868.60 Cash FlowGBX 32.93 per share Price / Cash Flow3.05 Book ValueGBX 5 per share Price / Book20.10Miscellaneous Outstanding Shares65,740,000Free FloatN/AMarket Cap£66.07 million OptionableNot Optionable Beta-0.02 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. James Gareth Short (Age 56)Co-Founder, CEO & Executive Director Comp: $246.15kMr. Paul AllenCo-FounderMr. Jonathan Paul Turner (Age 46)CFO & Director Iqbal GillChief Scientific OfficerMs. Kerin Williams (Age 54)Company Secretary Key CompetitorsAlliance PharmaLON:APHBeximco PharmaceuticalsLON:BXPAllergy TherapeuticsLON:AGYAnimalcare GroupLON:ANCRECO Animal Health GroupLON:EAHView All Competitors CEL Stock Analysis - Frequently Asked Questions Should I buy or sell Celadon Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celadon Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CEL shares. View CEL analyst ratings or view top-rated stocks. What is Celadon Pharmaceuticals' stock price target for 2024? 2 analysts have issued 1 year price targets for Celadon Pharmaceuticals' stock. Their CEL share price targets range from GBX 210 to GBX 235. On average, they predict the company's stock price to reach GBX 222.50 in the next twelve months. This suggests a possible upside of 121.4% from the stock's current price. View analysts price targets for CEL or view top-rated stocks among Wall Street analysts. How have CEL shares performed in 2024? Celadon Pharmaceuticals' stock was trading at GBX 115 at the beginning of 2024. Since then, CEL stock has decreased by 12.6% and is now trading at GBX 100.50. View the best growth stocks for 2024 here. How do I buy shares of Celadon Pharmaceuticals? Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:CEL) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsWARNING about the death of the U.S. dollar…Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
